Protara Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Protara Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2017-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- Protara Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2017-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- Protara Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2017-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- Protara Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2017-03-31 was 74.00K shares, a 1057.35% increase year-over-year.
- Protara Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 47.58K shares.
- Protara Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2017 was 74.00K shares, a 24.12% decline from fiscal 2016.
- Protara Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2016 was 97.52K shares, a 114.74% increase from fiscal 2015.
- Protara Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2015 was 45.41K shares, a 44.83% increase from fiscal 2014.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2024-12-31 | 47.58K shares 10-K · filed 2025-03-05 | |
| 2017-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | 74.00K shares 10-K · filed 2018-03-14 |
| 2017-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | 90.70K shares derived: sum of 4 quarters · filed 2017-11-07 |
| 2017-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | 99.01K shares derived: sum of 4 quarters · filed 2017-08-07 |
| 2017-03-31 | 74.00K shares 10-Q · filed 2017-05-10 | 165.13K shares derived: sum of 4 quarters · filed 2017-05-10 |
| 2016-12-31 | 16.70K shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | 97.52K shares 10-K · filed 2017-03-16 |
| 2016-09-30 | 8.32K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | 101.05K shares derived: sum of 4 quarters · filed 2016-11-07 |
| 2016-06-30 | 66.11K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | 113.76K shares derived: sum of 4 quarters · filed 2016-08-08 |
| 2016-03-31 | 6.39K shares 10-Q · filed 2016-05-09 | 51.57K shares derived: sum of 4 quarters · filed 2016-05-09 |
| 2015-12-31 | 20.23K shares derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-14 | 45.41K shares 10-K · filed 2016-03-14 |
| 2015-09-30 | 21.03K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | 55.84K shares derived: sum of 4 quarters · filed 2015-11-12 |
| 2015-06-30 | 3.92K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-13 | |
| 2015-03-31 | 236.00 shares 10-Q · filed 2015-05-13 | |
| 2014-12-31 | 30.65K shares derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-20 | 31.36K shares 10-K · filed 2015-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |